Validation of the Thai version of SARC-F, MSRA-7, and MSRA-5 questionnaires compared to AWGS 2019 and sarcopenia risks in older patients at a medical outpatient clinic

Phuriwat Akarapornkraiert a, Weerasak Muangpaisan b, *, Apinya Boonpeng c, Dao Daengdee c

a Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
b Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
c Bangkhunthian Geriatric Hospital, Bangkok Medical Service Department, Bangkok, Thailand

Article history:
Received 22 June 2020
Received in revised form 1 October 2020
Accepted 16 November 2020
Available online 26 November 2020

Keywords:
Sarcopenia
SARC-F
MSRA-7
MSRA-5
Questionnaires
Screening

Original article

Objective: To validate the Thai Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F), and 2 Mini Sarcopenia Risk Assessment (MSRA-5, and MSRA-7) questionnaires for sarcopenia screening in older patients in the medical outpatient setting, and to assess the improvements of the diagnostic accuracy by adapting the parameters in the SARC-F, MSRA-7, and MSRA-5 questionnaires. Risk factors for sarcopenia are also investigated.

Methods: Thai SARC-F, MSRA-7, and MSRA-5 questionnaires were translated backwards and forwards. Content validity and test–retest reliability were analyzed. Reliability analysis was used for SARC-F, MSRA-7, and MSRA-5 scores to increase the sensitivity and specificity. The sensitivity, specificity, likelihood ratio, and area under the receiver operating characteristic curves (AUCs) were analyzed.

Results: The prevalence of sarcopenia was 22.7% (65 of 286 patients). The sensitivity of the SARC-F, MSRA-7, and MSRA-5 questionnaires was 21.5%, 72.3%, and 61.5%, respectively. The specificity was 93.7%, 43%, and 67.4%, respectively. The AUCs were 0.58, 0.58, and 0.65, respectively. After weighting and adjusting the scores for the least responded-to items of the MSRA-5, the sensitivity increased to 82.6%, specificity to 43.4%, and AUC to 0.65. Multivariate analysis showed that the associated factors of sarcopenia were age (odds ratio (OR) = 5.92), body mass index < 18.5 (OR = 9.59), and currently working (OR = 0.11).

Conclusions: The modified MSRA-5 improved the sensitivity and diagnostic accuracy for screening for sarcopenia. It is potentially useful for screening for sarcopenia in settings with limited resources for bioelectrical impedance analysis, time, or health personnel.

© 2020 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Sarcopenia is a syndrome involving a decrease in muscle mass [1]. The reduction in muscle mass begins at the age of 50 years old, with the muscles decreasing by 1.5% per year, then by 3% per year in patients older than 60 years old. The effects of sarcopenia on older people include an increased risk of falls, rates of institutionalization and hospitalization, dependency, and mortality when compared to those who do not have sarcopenia [2–5]. The prevalence of sarcopenia in community-dwelling Thai adults aged 60 years old or over varies between 9.6% and 30.5% depending on participants’ characteristics and the measurement technique [6,7].

Currently, the gold standard diagnostic criteria for sarcopenia in Asian populations are the criteria proposed by the Asian Working Group for Sarcopenia 2019 (AWGS 2019) [8]. Diagnosis is based on the presence of decreased muscle mass and the presence of either low muscle strength or poor physical performance as follows. Muscle mass is measured by dual-energy X-ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA). Appendicular skeletal muscle mass (ASM) is defined as the sum of the muscle...
mass of the 4 limbs, and the appendicular skeletal mass index (ASM) can be calculated as ASM/height² (kg/m²). The cut-off values for BIA strength in men and women are less than 7 kg/m² and 5.7 kg/m², respectively. Low muscle strength is measured by using a hand-held dynamometer. The cut-off values for handgrip strength in men and women are less than 28.0 and 18.0 kg, respectively. A 6-meter usual gait speed of less than 1 m/second indicates poor physical performance.

The method of measuring sarcopenia using DXA or BIA has several limitations, such as the availability of the machine, and the cost of the routine examination in every older patient. Therefore, this limits the implementation of proactive routine screening. The SARC-F questionnaire [9] was consequently developed and used to screen sarcopenia in AWGS 2019 [8]. A meta-analysis of the SARC-F questionnaire in AWGS criteria demonstrated a sensitivity of 14% and specificity of 93% [10], which have limited its use in screening for sarcopenia due to the low sensitivity. In 2017, 2 Mini Sarcopenia Risk Assessment (MSRA-7 and MSRA-5) questionnaires were developed, and these demonstrated higher sensitivity than the SARC-F questionnaire [11]. The sensitivity of the MSRA-7 and MSRA-5 questionnaires was 86.9% and 90.2%, and the specificity was 39.6% and 70.6%, respectively [12].

Several factors were reported to be associated with sarcopenia, such as age [13–20], a low level of physical activity [13–19], low BMI [21,22], smoking [13,22], polypharmacy [14,22], diabetes [14,22], and multiple comorbidities [20]. On the other hand, a physically active condition and adequate energy intake (especially protein intake) may be protective factors for sarcopenia [23–25]. Studies in Thailand demonstrated older age, low BMI, and low physical performance were associated with sarcopenia, but they did not investigate the effects of the comorbidities, polypharmacy, and potentially protective factors [6,7]. Therefore, these factors are examined in this study.

These 3 questionnaires have never been translated into and validated in the Thai language. Consequently, the purpose of this study was to translate and validate these questionnaires for screening for sarcopenia in Thailand in places where there are limited resources and budget. This may be generalized to the whole country, especially in primary and community care. Furthermore, the associated factors for sarcopenia are also investigated for sarcopenic prevention and management.

2. Methods

2.1. Translation

The questionnaires were translated into Thai by a bilingual English teacher from the I-Style Language School. The SARC-F is composed of 5 questions (Table 1). In the question about strength (item 1), the explanation “Three 1.5-L bottles of drinking water” was added as an example of 10 pounds (4.5 kg). The total score ranges from a minimum of 0 points to a maximum of 10 points. A diagnosis of sarcopenia is made for a total score of 4 or higher. The MSRA-7 and MSRA-5 questionnaires are composed of 7 and 5 questions, respectively (Table 2). The total score for the MSRA-7 ranges from a minimum of 0 points to a maximum of 40 points, and a total score of 30 points or less indicates sarcopenia. The total score for the MSRA-5 ranges from a minimum of 0 points to a maximum of 60 points, and a total score of 45 points or less indicates sarcopenia. A blind backward translation was performed by the bilingual pharmacist. The blind content validity index (CVI) was performed after a forward and backward translation by 3 consultant geriatricians for providing reliable empirical information regarding the quality of the instruments. The acceptable CVI was 0.8 or more [26,27].

2.2. Study design and participants

We conducted a cross-sectional study at Bangkhunthian Geriatric Hospital and Siriraj Hospital in Bangkok, Thailand. Bangkhunthian Geriatric Hospital represents a population group in a small hospital, while Siriraj Hospital is a tertiary hospital and a medical school representing a population group in a large hospital. The Institutional Review Board, Faculty of Medicine Siriraj Hospital (SIRB) approved the human research ethics for this study (COA no. Si 538/2019). Written informed consent was obtained from all participants (or their legal proxies). From September to December 2019, general medicine outpatients (OPD) aged 60 years old or older were approached and recruited through a convenient sampling method if they met the inclusion criteria. Individuals with the following conditions were excluded: patients who could not stand, walk, or hold a grip, or who had an implanted pacemaker or metallic device, severe dementia, or were unable to communicate in the Thai language.

2.3. Measurement of muscle mass, handgrip strength, and 6 meter usual gait speed

The total appendicular skeletal muscle mass (ASM) was measured using bioelectrical impedance analysis (BIA) (MC-780 MA, TANITA, Tokyo, Japan), and then, the skeletal muscle mass index (SMI) was calculated as 
\[\text{SMI (kg/m}^2\) = \text{ASM/height}^2\]. The handgrip strength was measured using a handheld dynamometer (Grip-D, Takei Scientific Instruments Co., Ltd, Tokyo, Japan). The measurements were performed 3 times on the dominant hand while the subject was seated with the elbow flexed at a 90° angle, and the wrist placed in a neutral position. The mean of the dyna-
meter values was applied for the analysis [28]. Six-meter usual gait speed was calculated by dividing the time it took patients to walk a 6 meter (m) section of this course by the number of seconds it took to complete the section (using the data from the 2 m and 8 m marks from a 10 m distance). When the speed was < 1 m/second, the patient was considered to have low physical performance. All the tests were performed by 2 trained assessors, one of whom was a geriatric fellow and the other a geriatric nurse.

| Table 1 |
| SARC-F questionnaire. |
| --- |
| **1. Strength** | How much difficulty do you have in lifting and carrying 10 pounds? |
| **None** | 0; Some | 1; A lot or unable |
| **2. Assistance in walking** | How much difficulty do you have walking across a room? |
| **None** | 0; Some | 1; A lot, use aids, or unable |
| **3. Rise from a chair** | How much difficulty do you have transferring from a chair or bed? |
| **None** | 0; Some | 1; A lot or unable without help |
| **4. Climb stairs** | How much difficulty do you have climbing a flight of 10 stairs? |
| **None** | 0; Some | 1; A lot or unable |
| **5. Falls** | How many times have you fallen in the past year? |
| **None** | 0; 1–3 falls | 1; 4 or more falls |

The maximum score is 10. A score of 4 or more may suggest sarcopenia.

SARC-F, Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls.
2.4. Covariates

The following covariates were collected from face-to-face interviews: age, gender, educational background, working status, activities of daily living questionnaires (The Barthel Index for Activities of Daily Living: BADL [30] and The Lawton Instrumental Activities of Daily Living Scale: IADL [30]), self-reported number of falls and hospitalization, self-reported daily exertion (low, moderate, or good), Thai Mental State Examination (TMSE), number of daily drugs as revealed in a face-to-face interview and in a medical records review (≥ 5 drugs were defined as polypharmacy), and comorbid conditions as revealed in a face-to-face interview and by a medical records review. The question regarding smoking habits was phrased as follows: “Do you currently smoke tobacco habitually?” and could be answered with a “yes” or “no” or “already quit”. The question about drinking habits was phrased as follows: “Do you have a habit of drinking alcohol?” and was also answerable with a “yes” or “no” or “already quit”. If the answer was “yes”, the amount and frequency of drinking would be further asked. The BMI calculation was thus 286 participants.

The statistical analysis was performed by using PASW Statistics 18.0 (SPSS, Inc., Chicago, IL, USA).

3. Results

3.1. Characteristics of the study population

We translated the SARC-F, MSRA-7, and MSRA-5 questionnaires from English into Thai language and the forward CVI from the 3 geriatricians was good (forward CVI for SARC-F = 0.93, MSRA-7 = 1.00, and MSRA-5 = 1.00). Then we translated the questionnaires backward into English language and the CVI was also good (backward CVI for SARC-F = 1.00, MSRA-7 = 0.95, and MSRA-5 = 0.93). The test–retest reliability of SARC-F was 72.7% (Kappa coefficient = –0.14), MSRA-7 was 90.9% (Kappa coefficient = 0.81), and MSRA-5 was 81.8% (Kappa coefficient = 0.61).

We included 286 participants (119 men and 167 women, mean age: 71.8 ± 7.8 years old). Table 3 presents the characteristics of the participants categorized by the presence or absence of sarcopenia according to the AWGS 2019 criteria. Participants with sarcopenia were older and had a lower BMI and lower TMSE. Furthermore, participants in the sarcopenia group had a higher proportion of dementia, stroke, osteoporosis, current smokers, and had the status of not currently working compared to those without sarcopenia. As compared to the non-sarcopenia groups, the sarcopenia group had significantly higher Thai SARC-F scores and lower MSRA-7 and MSRA-5 scores.

3.2. Prevalence of sarcopenia

The prevalence of sarcopenia was 22.7% (24.4% in men and 21.6% in women). Table 4 presents the results for the muscle mass, on the basis of the presence or absence of sarcopenia. Differences in characteristics between participants were compared using the chi-square test or 2-sample t-test. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and area under the receiver operating characteristic curve (AUC) of the 3 questionnaires were calculated using the diagnostic criteria for sarcopenia, with AWGS 2019 as the reference standard. We also analyzed the risk factors for sarcopenia by using univariate and multivariate logistic regression models. The statistical analysis was performed by using PASW Statistics 18.0 (SPSS, Inc., Chicago, IL, USA).

### Table 2

| Question                                                                 | Score (7 items) | Score (5 items) |
|--------------------------------------------------------------------------|----------------|----------------|
| 1-How old are you?                                                       | ≥ 70 years old  | 0              |
| < 70 years old                                                          | 0              |
| 2-Were you hospitalized in the last year?                                | -Yes, one hospitalization | 5          |
| -No                                                                      | 0              |
| 3-What is your activity level?                                           | -I'm able to walk less than 1000 m | 0          |
| -I'm able to walk more than 1000 m                                      | 0              |
| 4-Do you eat 3 meals per day regularly?                                  | -No, up to twice per week I skip a meal (for example I skip breakfast or I have only milky coffee or soup for dinner) | 0          |
| -Yes                                                                     | 0              |
| 5-Do you consume any of the following?                                   | -Milk or dairy products (yogurt, cheese), but not every day | 0          |
| -Milk or dairy products (yogurt, cheese) at least once per day           | 0              |
| 6- Do you consume any of the following? 1- Yes, one hospitalization      | -Poultry, meat, fish, eggs, legumes, ragout or ham, but not every day | 0          |
| -Poultry, meat, fish, eggs, legumes, ragout or ham at least once per day | 0              |
| 7-Did you lose weight in the last year?                                  | > 2 kg         | 0              |
| ≤ 2 kg                                                                   | 0              |
| Maximum score for MSRA-7 is 40. A score of 30 or less may suggest sarcopenia. |               |
| Maximum score for MSRA-5 is 60. A score of 45 or less may suggest sarcopenia. |               |

MSRA, The Mini Sarcopenia Risk Assessment.
Table 3
Characteristics of the study population according to the Asian Working Group for Sarcopenia (AWGS) 2019 criteria of sarcopenia.

| Variable                        | No sarcopenia (n = 221, 77.3%) | Sarcopenia (n = 65, 22.7%) | P-value |
|---------------------------------|--------------------------------|---------------------------|---------|
| Age, yr                         | 70.1 (6.8)                     | 77.5 (8.5)                | < 0.001 |
| Women                           | 131 (59.3)                     | 36 (55.4)                 | 0.58    |
| BMI, kg/m²                      | 24.9 (3.9)                     | 20.7 (2.7)                | 0.05    |
| Education ≤ 4 years             | 84 (38)                        | 27 (41.5)                 | 0.61    |
| Currently working               | 57 (25.8)                      | 3 (4.6)                   | < 0.001 |
| Medical history                 |                                |                           |         |
| Hypertension                    | 126 (57)                       | 39 (60)                   | 0.67    |
| Hyperlipidemia                  | 141 (63.8)                     | 37 (56.9)                 | 0.32    |
| Diabetes                        | 54 (24.4)                      | 13 (20)                   | 0.46    |
| AD and related dementia         | 24 (10.9)                      | 17 (26.2)                 | 0.002   |
| Stroke or TIA                   | 16 (7.2)                       | 11 (16.9)                 | 0.019   |
| Knee osteoarthritis             | 44 (19.9)                      | 10 (15.4)                 | 0.41    |
| Osteoporosis                    | 10 (4.5)                       | 9 (13.8)                  | 0.008   |
| Coronary heart disease          | 6 (2.7)                        | 3 (4.6)                   | 0.44    |
| Cancer                          | 12 (5.4)                       | 4 (6.2)                   | 0.823   |
| Barthel ADL ≤ 12/20             | 2 (0.9)                        | 2 (3.1)                   | 0.19    |
| Instrumental ADL ≤ 4/8          | 19 (8.6)                       | 19 (29.2)                 | < 0.001 |
| Polypharmacy                    | 83 (37.6)                      | 34 (52.3)                 | 0.03    |
| Number of falls per year        |                                |                           | 0.95    |
| 0                               | 159 (72.0)                     | 47 (72.3)                 |         |
| 1                               | 35 (15.8)                      | 13 (20.0)                 |         |
| ≥ 2                             | 27 (12.2)                      | 5 (7.7)                   | 0.89    |
| Hospitalization ≥ 1 in 1 year   | 39 (17.6)                      | 11 (16.9)                 | 0.001   |
| Current smoker                  | 1 (0.5)                        | 5 (7.7)                   |         |
| Current alcohol drinker         | 23 (10.4)                      | 5 (7.7)                   |         |
| TMSE                            | 26.5 (3.5)                     | 24.2 (5.6)                | < 0.001 |
| SARC-F score                    | 1.2 (1.6)                      | 2 (1.8)                   | < 0.001 |
| MSRA-7                          | 31.3 (5.6)                     | 28.2 (6.1)                | 0.03    |
| MSRA-5                          | 51.0 (9.6)                     | 44.7 (10.9)               | < 0.001 |

Values are presented as mean ± standard deviation or number (%).

Table 4
Muscle mass, handgrip strength, and 6-meter usual gait speed.

| Components of sarcopenia | Men (n) | Women (n) | All (n) |
|--------------------------|---------|-----------|---------|
| Muscle mass              |         |           |         |
| Normal                   | 84 (70.6) | 119 (71.3) | 203 (71) |
| Low                      | 35 (29.4) | 48 (28.7)  | 83 (29)  |
| Handgrip strength        |         |           |         |
| Normal                   | 72 (60.5) | 96 (57.5)  | 168 (58.7)|
| Low                      | 47 (39.5) | 71 (42.5)  | 118 (41.3)|
| Six-meter usual gait speed|         |           |         |
| Normal                   | 39 (32.8) | 48 (28.7)  | 87 (30.4)|
| Low                      | 80 (67.2) | 119 (71.3) | 199 (69.6)|
| Sarcopenia               |         |           |         |
| No                       | 90 (75.6) | 131 (78.4) | 221 (77.3)|
| Yes                      | 29 (24.4) | 36 (21.6)  | 65 (22.7)|
| Questionnaires: positive for sarcopenia |         |           |         |
| SARC-F                   | 10 (34.5)| 4 (11.1)   | 14 (21.5)|
| MSRA-7                   | 28 (86.2) | 22 (61.1)  | 50 (78.6)|
| MSRA-5                   | 22 (75.9) | 18 (50.0)  | 40 (61.5)|

Values are presented as number (%).

The classifications of sarcopenia using the SARC-F, MSRA-7, and MSRA-5 were tabulated according to the AWGS 2019 criteria (Table 5). The sensitivity, specificity, and AUC of the SARC-F were 21.5%, 93.7%, and 0.576, respectively. The sensitivity, specificity, and AUC of the MSRA-7 were 72.3%, 43%, and 0.576, respectively. The sensitivity, specificity, and AUC of the MSRA-7 were 61.5%, 67.4%, and 0.645, respectively. Due to the low sensitivity of MSRA-5 as compared to the result from the previous study (sensitivity 90.2%, specificity 70.6%) [32], the reliability analysis was checked to evaluate the Cronbach alpha coefficient overall to provide highest correlation. We weighted and adjusted the scores of the least responded-to items of the MSRA-5. Thus for MSRA-5 “Question 2: Were you hospitalized in the last year?”, we adjusted the scores from 15 to 2 points if the answer was no (not hospitalized), and the score was 0 points if the answer was yes. Also, for “Question 4: Do you eat 3 meals per day regularly?”, we adjusted the score from 15 to 2 points if the answer was yes (regularly eat 3 meals per day), and the score was 0 points if the answer was no. With the modified MSRA-5, using a cut-off points of less than or equal to 30 as a positive indicator for sarcopenia, the sensitivity increased to 86.2% and the AUC increased to 0.648. As the AWGS 2019 revises the diagnostic algorithm of the previous definition of sarcopenia and it does not include age in settings, we therefore also compared scores of MSRA-7, MSRA-5 and modified MSRA-5 questionnaires without Question 1 “How old are you?” with SARC-F to investigate sensitivity and diagnostic accuracy of sarcopenia. Aiming at the highest sensitivity to be a screening test, the best AUC with the highest sensitivity is still shown in modified MSRA-5 (Table 5).
to its relatively low sensitivity from our findings, MSRA-7 and SARC-F (0.58 and 0.58, respectively). However, due to its sensitivity value than MSRA-7 (61.5% vs 72.3%). However, MSRA-5 exhibited a significantly larger than those in comparison with non-smokers. In smokers, the muscle metabolic alterations were found in the muscle biopsies of smokers [37]. In their report on a one-year longitudinal study, Rom O et al. [38] indicated that muscle mass and muscle strength were increased among quitters when compared with continued smokers. However, that study was conducted in young participants (mean age 44 ± 12 years old), and further study should be conducted in older adults.

The prevalence of sarcopenia when using AWGS 2019 for the diagnosis of sarcopenia in a previous study by Kim M et al in South Korea in 2020 [39] was not much lower than in our study (21.3% vs 22.1%) in Korea in 2020 [39] was not much lower than in our study (21.3% vs 22.1%).

3.4. Associated factors for sarcopenia

Univariate logistic regression revealed that age 70–79 years old, age ≥ 80 years old, low BMI (<18.5 kg/m²), medical history of dementia and osteoporosis, TMSE ≤ 23, polypharmacy (drugs ≥ 5/day), low physical activity (self-reported), and current smoker were significantly associated with sarcopenia. Currently working was a possible protective factor for sarcopenia. Multiple logistic regression analysis revealed that age ≥ 80 years old and low BMI (<18.5 kg/m²) were associated factors of sarcopenia (Table 6).

4. Discussion

Our study indicated that MSRA-5 had less sensitivity diagnostic value than MSRA-7 (61.5% vs 72.3%). However, MSRA-5 exhibited only 5 items, which made it simpler than MSRA-7. We also found that the AUCs of MSRA-5 (0.65) were significantly larger than those of MSRA-7 and SARC-F (0.58 and 0.58, respectively). However, due to its sensitivity, low sensitivity from our findings, MSRA-5 may be less appropriate for screening for sarcopenia in clinical practice. In order to increase the sensitivity of MSRA-5, we adjusted the least respondents to questions, i.e., 2 and 4, from 0 to 15 points to 0–2 points. The modified MSRA-5 total points were changed from 60 points to 34 points. Then, we adjusted the cut-off points for the diagnosis of sarcopenia from 45 points or less to 30 points or less. The modified MSRA-5 had a higher sensitivity than the original MSRA-5 (86.2% vs 61.5%) and had acceptable specificity (43.4%). The AUCs of the modified MSRA-5 showed the same values as for the original MSRA-5 [0.65 (95% CI = 0.58–0.72) vs 0.65 (95% CI = 0.57–0.72)].

We found that the associated factors for sarcopenia were age ≥ 80 years old and a low BMI (<18.5 kg/m²) when we analyzed the data using the multivariate logistic regression model. The factors were similar to those reported in previous studies [7,13–22].

Table 5

| Tests                  | Sensitivity % | Specificity % | PPV % | NPV % | PLR (95% CI) | NLR (95% CI) | AUC (95% CI) |
|------------------------|--------------|--------------|-------|-------|--------------|--------------|--------------|
| SARC-F                 | 21.5         | 93.7         | 50    | 80.3  | 3.4 (1.7–6.8) | 0.8 (0.7–1.0) | 0.58         |
| MSRA-7 (Original)      | 72.3         | 43.0         | 27.1  | 84.1  | 1.3 (1.1–1.5) | 0.6 (0.4–1.0) | 0.58         |
| MSRA-7 (no original question 1) | 50.8     | 67.0         | 31.1  | 82.2  | 1.5 (1.1–2.1) | 0.7 (0.6–1.0) | 0.59         |
| MSRA-5 (Original)      | 61.5         | 67.4         | 35.7  | 85.7  | 1.9 (1.4–2.5) | 0.6 (0.4–0.8) | 0.65         |
| MSRA-5 (no original question 1) | 61.5     | 63.8         | 33.9  | 85.5  | 1.7 (1.4–2.3) | 0.6 (0.4–0.8) | 0.63         |
| Modified MSRA-5        | 86.2         | 43.4         | 31.0  | 91.4  | 1.5 (1.3–1.8) | 0.3 (0.2–0.6) | 0.65         |
| Modified MSRA-5 (no original question 1) | 63.1     | 63.8         | 33.9  | 85.5  | 1.7 (1.4–2.3) | 0.6 (0.4–0.8) | 0.63         |

Values are presented as number (%).
SARC-F, Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls; MSRA, The Mini Sarcopenia Risk Assessment; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; CI, confidence interval; AUC, area under receiver operating characteristic curve.

Table 6

| Variable                      | Univariate analysis odds ratio (95% CI) | P-value | Multivariate analysis odds ratio (95% CI) | P-value |
|-------------------------------|----------------------------------------|---------|-----------------------------------------|---------|
| Age, yr                       |                                        |         |                                         |         |
| 60–69                         | 1.00                                   |         | 1.00                                    |         |
| 70–79                         | 2.34 (1.12–4.87)                       | 0.02    | 1.87 (0.81–4.34)                       | 0.14    |
| ≥ 80                          | 10.71 (4.96–23.17)                     | <0.001  | 5.92 (2.35–4.87)                       | <0.001  |
| BMI < 18.5 kg/m²              | 11.71 (4.67–29.63)                     | <0.001  | 9.59 (2.91–31.61)                      | <0.001  |
| Currently working             | 0.14 (0.04–0.46)                       | 0.001   | 0.13 (0.03–0.66)                       | 0.01    |
| Medical history of smoking    |                                        |         |                                         |         |
| Dementia                      | 2.91 (1.45–5.84)                       | 0.003   | 0.85 (0.32–2.28)                       | 0.75    |
| Osteoporosis                  | 3.39 (1.32–8.75)                       | 0.01    | 1.59 (0.5–5.08)                        | 0.43    |
| TMSE ≤ 23                     | 3.24 (1.65–6.38)                       | 0.001   | 1.95 (0.76–4.96)                       | 0.16    |
| Medication ≥ 5/day            | 1.82 (1.04–3.19)                       | 0.04    | 1.11 (0.55–2.27)                       | 0.77    |
| Self-reported low physical activity | 2.43 (1.37–4.33)       | 0.003   | 1.79 (0.87–3.67)                       | 0.11    |
| Current smoker                | 19.88 (2.26–174.74)                    | 0.007   | 13.22 (0.78–224.87)                    | 0.07    |

CI, confidence interval; BMI, body mass index; TMSE, Thai mental state examination.

Skeletal muscle mass and strength decline with age-related changes in biology [16]. The age-related loss of muscle mass is due to a decrease in myofiber size and number. The prevention and treatment of sarcopenia rely on the principle of non-pharmacological intervention [8,33]. The European Society of Clinical Nutrition and Metabolism guideline on clinical nutrition and hydration in geriatrics (ESPEN 2019) indicates that weight loss and inadequate nutrition are the important contributing factors of sarcopenia [34]. A combination of a balanced, nutrient-rich diet providing adequate energy and protein intake is well known for the prevention of muscle loss [34,35]. Both resistance and strengthening exercises have been shown to be successful interventions in the prevention and treatment of low muscle strength [36]. Though nutritional or exercise interventions and combined intervention variably affect sarcopenia, these are still recommended for the prevention and treatment of sarcopenia before the incidence of falls, dependency, or mortality occurs [36]. Being a current smoker in our study tended to be a risk factor of sarcopenia but it was not statically significant according to the multivariate analysis [OR = 13.22 (95% CI = 0.78–224.87)]. As mentioned above, smoking is an important risk factor for sarcopenia [13,22]. Structural and metabolic alterations were found in the muscle biopsies of smokers in comparison with non-smokers. In smokers, the muscle fibers cross-sectional area was decreased and lactate dehydrogenase (LDH) activity that indicated muscle damage was increased in smokers [37]. In their report on a one-year longitudinal study, Rom O et al. [38] indicated that muscle mass and muscle strength were increased among quitters when compared with continued smokers. However, that study was conducted in young participants (mean age 44 ± 12 years old), and further study should be conducted in older adults.

The prevalence of sarcopenia when using AWGS 2019 for the diagnosis of sarcopenia in a previous study by Kim M et al in South Korea in 2020 [39] was not much lower than in our study (21.3% vs 22.1%).
24.4% in men and 13.8% vs 21.6% in women). Their study recruited the whole range of community-dwelling older adults, who were classified as those at risk of sarcopenia according to a low calf circumference, SARC-F questionnaire, and SARC-F plus calf circumference (SARC-Calf). The lower prevalence in that study may be due to the participants from the community who had less comorbidities and from false negative sarcopenia from those screening tools (calf circumference, SARC-F, and SARC-Calf). The prevalence of sarcopenia from an outpatient clinic was studied by Savas S et al in Turkey in 2019 [40]. They used the European working group on sarcopenia in older people (EWGSOP 2) [41] and regional cut-off values of muscle mass and handgrip strength for the diagnosis of sarcopenia. The prevalence of sarcopenia in their study was higher than in our study (41.1% vs 22.7%) because they used a skeletal muscle mass index (SMMI) instead of ASMl and used a higher regional cut-off SMMI (< 9.2 vs < 7 kg/m² in men and < 7.4 vs < 5.7 kg/m²).

In Thailand, the prevalence of sarcopenia is not the same as in previous studies that reported a prevalence of 9.6% [6] and 30.5% [7]. This was probably caused by the different populations and the sarcopenia assessment method. The study by Promklng D et al [6] recruited participants from the community that are likely to be different from the participants in an outpatient clinic due to them having fewer comorbidities. The prevalence of sarcopenia reported by Khongsri N et al [7] was higher than in our study. This may be attributed to using whole-body muscle mass instead of limb mass, and as the BIA machine in their study used to measure muscle mass was a portable BIA system (Model 450 Biodynamics, Seattle, WA, USA), which does not measure appendicular skeletal muscle mass.

Some limitations of this study should be mentioned. Firstly, as convenience sampling was applied, selection bias may be present, resulting in an overrepresentation of healthier people as compared to other older patients in the outpatient clinic. Secondly, we studied the older patients from the general medicine outpatient where there was expected to be higher prevalence of sarcopenia. Therefore, the generalizability of the results to other settings should take this issue into consideration. Thirdly, some items were not suitable to older Thai population eg, questions about the consumption of milk or dairy products in MSRA-7 which is not common in Thai older people. Lastly, the test of this modified version of MSRA should be performed in second independent samples. This process is under ongoing study.

5. Conclusions

The SARC-F questionnaire was used to screen for sarcopenia according to AWGS 2019, but SARC-F alone was not adequate for screening for sarcopenia due to its low sensitivity; whereas MSRA-7 may provide better sensitivity in our study with limited specificity. MSRA-5 showed lower sensitivity than MSRA-7 but a higher specificity and AUC, whereas the modified MSRA-5 showed improved sensitivity and an improvement in the overall diagnostic accuracy for screening for sarcopenia. It would therefore be potentially useful for screening for sarcopenia in settings with limited resources of bioelectrical impedance analysis, limited time, or limited availability of health personnel. Further study is needed to test its use with a community-dwelling Thai older population.

CRediT author statement

Puriwit Akarapornkrailet: Conceptualization, Methodology, Writing – original draft, Software, Validation, Formal analysis, Visualization, Investigation, Resources, Data curation, Writing – review & editing, Project administration. Weerasak Muangpaisan: Conceptualization, Methodology, Writing – original draft, Visualization, Investigation, Resources, Data curation, Writing – review & editing, Supervision, Project administration. Apinya Boonpeng: Conceptualization, Methodology, Investigation, Writing – review & editing. Dao Daengdee: Conceptualization, Methodology, Investigation, Writing – review & editing.

Conflicts of interest

The authors declare no competing interests.

Acknowledgments

Funding source: Research Development Grant (R016231066), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

The authors thank the participants of the study and the staff at the Geriatric Clinic of Siriraj Hospital and Bangkhunthian Geriatric Hospital for their contribution to data collection. The authors gratefully acknowledge Dr. Harisd Phannarus, Dr. Apinanatna Apiwathanant, and Dr. Ekkaphop Morkphrom for providing the content validity index of the translated version of the SARC-F and MSRA. ORCID Phuiriwat Akarapornkrailet: 0000-0003-4233-9144. Weerasak Muangpaisan: 0000-0001-5863-3597. Apinya Boonpeng: 0000-0001-7526-5095. Dao Daengdee: 0000-0002-8387-9449.

References

[1] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 2010;39: 412–23.
[2] Limpawattana P, Kotruch P, Pongchaipakul C. Sarcopenia in Asia. Osteoporos Sarcopenia 2015;1:92–7.
[3] Kim TN, Choi KM. Sarcopenia: definition, epidemiology, and pathophysiology. J Bone Metab 2013;20:1–10.
[4] Sanchez-Rodriguez D, Marco E, Miralles R, Fayos M, Mojal S, Alvarado M, et al. Sarcopenia, physical rehabilitation and functional outcomes of patients in a subacute geriatric care unit. Arch Gerontol Geriatr 2014;59:39–43.
[5] Landi F, Cruz-Jentoff AJ, Liperoti R, Russo A, Giovannini S, Tosato M, et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from iLSIRENTE study. Age Ageing 2013;42:203–9.
[6] Promklng D, Paiseu N, Maruo SJ, Tantiprasoplap S. Factors associated with sarcopenia amongst older adults in congested communities in Bangkok. Thai J Nurs Council 2018;33:49–60.
[7] Khongsri N, Tongsuntud S, Limampai P, Kuptniratsaikul V. The prevalence of sarcopenia and related factors in a community-dwelling elders Thai population. Osteoporos Sarcopenia 2016;2:110–5.
[8] Chen IK, WO J, Assantachai P, Puyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21:300–7 e2.
[9] Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 2013;14:531–2.
[10] Ida S, Kaneko R, Murata K. SARC-F for screening of sarcopenia among older adults: a meta-analysis of screening test accuracy. J Am Med Dir Assoc 2018;19:985–9.
[11] Rossi AP, Micciolo R, Rubele S, Fantin F, Caliari C, Zoico E, et al. Assessing the risk of sarcopenia in the elderly: the mini sarcopenia risk assessment (MSRA) questionnaire. J Nutr Health Aging 2017;21:743–9.
[12] Yang M, Hu X, Xie L, Zhang L, Zhou J, Lin J, et al. Comparing mini sarcopenia risk assessment with SARC-F for screening sarcopenia in community-dwelling older adults. J Am Med Dir Assoc 2019;20:53–7.
[13] Woo J, Leung J, Sham A, Kwok T. Defining sarcopenia in terms of risk of physical limitations: a 5-Year follow-up study of 3,153 Chinese men and women. J Am Geriatr Soc 2009;57:2224–11.
[14] Konig M, Spira D, Demuth I, Steinhaen-Thiessen E, Norman K. Polypharmacy as a risk factor for clinically relevant sarcopenia: results from the Berlin aging study B. J Gerontol A Biol Sci Med Sci 2017;73:117–22.
[15] Santilli V, Bernetti A, Mangone M, Paoloni M. Clinical definition of sarcopenia. Clin Cases Miner Bone Metabol 2014;11:177–80.
[16] Walston JD. Sarcopenia in older adults. Curr Opin Rheumatol 2012;24:623–7.
[17] Sayer AA, Robinson SM, Patel HP, Shavlakadze T, Cooper C, Grounds MD. New horizons in the pathogenesis, diagnosis and management of sarcopenia. Age Ageing 2013;42:145–50.
[18] Beasley JM, Shikany JM, Thomson CA. The role of dietary protein intake in the prevention of sarcopenia of aging. Nutr Clin Pract 2013;28:684–90.
[19] Hida T, Harada A, Imagama S, Ishiguro N. Managing sarcopenia and its related fractures to improve quality of life in geriatric populations. Aging Dis 2014;5:226–37.

[20] Newman AB, Kupelian V, Visser M, Simonsick E, Goodpaster B, Nevitt M, et al. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc 2003;51:1602–9.

[21] Iannuzzi-Surich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci 2002;57:M772–7.

[22] Su Y, Hirayama K, Han TF, Izutsu M, Yuki M. Sarcopenia prevalence and risk factors among Japanese community dwelling older adults living in a snow-covered city according to EWGSOP2. J Clin Med 2019;8:291–303.

[23] Xia Z, Meng L, Man Q, Li L, Song P, Li Y, et al. Analysis of the dietary factors on sarcopenia in elderly in Beijing. Wei Sheng Yan Jiu 2016;45:388–93.

[24] Bloom I, Shand C, Cooper C, Robinson S, Baird J. Diet quality and sarcopenia in older adults: a systematic review. Nutrients 2018;10.

[25] Yang LJ, Wu GH, Yang YL, Wu YH, Zhang L, Wang MH, et al. Nutrition, physical exercise, and the prevalence of sarcopenia in elderly residents in nursing homes in China. Med Sci Mon Int Med J 2019;25:4390–9.

[26] Polit DF, Beck CT. In: Nursing research: principles and methods. seventh ed. Philadelphia: Lippincott, Williams & Wilkins; 2004.

[27] Polit DF, Beck CT. The content validity index: are you sure you know what’s being reported? Critique and recommendations. Res Nurs Health 2006;29:489–97.

[28] Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardized approach. Age Ageing 2011;40:423–9.

[29] Mahoney F, Barthel D. Functional evaluation: the Barthel index. Md State Med J 1965;14:81–5.

[30] Graf C. The Lawton instrumental activities of daily living scale. Am J Nurs 2008;108:52–62. quiz -3.

[31] Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inf 2014;48:193–204.

[32] Yang M, Hu X, Xie L, Zhang L, Zhou J, Lin J, et al. Validation of the Chinese version of the Mini Sarcopenia Risk Assessment questionnaire in community-dwelling older adults. Medicine (Baltim) 2018;97:e12426.

[33] Dhillion RJ, Hasni S. Pathogenesis and management of sarcopenia. Clin Geriatr Med 2017;33:17–26.

[34] Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr 2019;38:10–47.

[35] Naase DB, Volpe SL. Protein and exercise in the prevention of sarcopenia and aging. Nutr Res 2017;40:1–20.

[36] Antom SD, Hida A, Manikowski R, Layne A, Solberg LM, Maïnous AG, et al. Nutrition and exercise in sarcopenia. Curr Protein Pept Sci 2018;19:649–67.

[37] Montes de Oca M, Loeb E, Torres SH, De Sanctis J, Hernández N, Talamo C. Peripheral muscle alterations in non-COPD smokers. Chest 2008;133:13–8.

[38] Rom O, Reznick AZ, Kedar Z, Karkabi K, Aizenbud D. Smoking cessation-related weight gain—beneficial effects on muscle mass, strength and bone health. Addiction 2015;110:326–35.

[39] Kim M, Won CW. Sarcopenia in Korean community-dwelling adults aged 70 years and older: Application of screening and diagnostic tools from the Asian Working Group for Sarcopenia 2019 Update. J Am Med Dir Assoc 2020;21:752–8.

[40] Savas S, Tajo-Aguilera E, Sarac FZ, Akcicek F. A cross-sectional study on sarcopenia using EWGSOP1 and EWGSOP2 criteria with regional thresholds and different adjustments in a specific geriatric outpatient clinic. Eur Geriatr Med 2020;11:239–46.

[41] Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16–31.